Compare GEVO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | PRTA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | Ireland |
| Employees | 151 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.8M | 539.9M |
| IPO Year | 2010 | 2013 |
| Metric | GEVO | PRTA |
|---|---|---|
| Price | $1.98 | $10.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $6.42 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 4.4M | 462.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $711,000.00 | ★ $814,000.00 |
| Revenue This Year | $19.44 | $1,111.38 |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $4.32 |
| 52 Week High | $2.97 | $11.69 |
| Indicator | GEVO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 64.85 |
| Support Level | $1.94 | $9.69 |
| Resistance Level | $2.19 | $10.90 |
| Average True Range (ATR) | 0.20 | 0.41 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 10.36 | 95.21 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.